This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
by Kinjel Shah
LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.
pharmaceuticals
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
by Zacks Equity Research
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
biotechnology biotechs medical pharmaceuticals
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
by Nalak Das
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
medical medical-devices pharmaceuticals
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
biotechnology biotechs medical pharmaceuticals
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
by Aparajita Dutta
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
etfs pharmaceuticals
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
by Sundeep Ganoria
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
biotechs medical pharmaceuticals
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
biotechnology biotechs medical pharmaceuticals
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
by Sundeep Ganoria
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
biotechs medical pharmaceuticals
BAYRY's 2025 Revival: Will the Momentum Continue in 2026?
by Zacks Equity Research
BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.
cell-therapy medical pharmaceuticals